Virpax Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing pharmaceutical product candidates for pain management by developing and delivering non-opioid and non-addictive pharmaceutical products. Its products include Epoladerm, OSF200, Probudur, NES100, PES200 and MMS019. Epoladermis is developed as a topical nonsteroidal anti-inflammatory drug (NSAID) treatment for acute pain. OSF200 utilizes the same transdermal delivery system as Epoladerm as a twice daily topical treatment for chronic osteoarthritis of the knee. Probudur is a drug product candidate based on a liposomal delivery system utilizing large multi-vesicular vesicles (LMVVs) encapsulating a dose of the local anesthetic bupivacaine. NES100 is a nanotechnology-based intranasal spray drug product candidate. PES200 enables the delivery of a metabolically labile peptide drug into the brain. MMS019 is a molecular masking spray, which is developed as an anti-viral barrier.